Commodore Capital LP Sells 325,000 Shares of Xenon Pharmaceuticals Inc. $XENE

Commodore Capital LP trimmed its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 10.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,700,000 shares of the biopharmaceutical company’s stock after selling 325,000 shares during the period. Xenon Pharmaceuticals makes up approximately 5.3% of Commodore Capital LP’s holdings, making the stock its 3rd largest holding. Commodore Capital LP’s holdings in Xenon Pharmaceuticals were worth $108,405,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in XENE. Neo Ivy Capital Management bought a new stake in shares of Xenon Pharmaceuticals during the third quarter valued at approximately $2,001,000. JPMorgan Chase & Co. lifted its position in Xenon Pharmaceuticals by 11.3% in the third quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company’s stock worth $56,171,000 after purchasing an additional 142,452 shares during the period. Westfield Capital Management Co. LP lifted its position in Xenon Pharmaceuticals by 4.6% in the third quarter. Westfield Capital Management Co. LP now owns 1,206,066 shares of the biopharmaceutical company’s stock worth $48,424,000 after purchasing an additional 53,461 shares during the period. Marshall Wace LLP boosted its stake in Xenon Pharmaceuticals by 34.6% during the second quarter. Marshall Wace LLP now owns 1,020,254 shares of the biopharmaceutical company’s stock worth $31,934,000 after buying an additional 262,109 shares in the last quarter. Finally, American Century Companies Inc. acquired a new stake in Xenon Pharmaceuticals during the second quarter worth $21,280,000. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Xenon Pharmaceuticals stock opened at $55.23 on Friday. The firm has a market capitalization of $4.59 billion, a P/E ratio of -12.67 and a beta of 0.91. The stock has a fifty day moving average price of $43.71 and a two-hundred day moving average price of $41.94. Xenon Pharmaceuticals Inc. has a 52-week low of $26.74 and a 52-week high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same quarter in the prior year, the business posted ($0.84) EPS. On average, equities research analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Insider Activity at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 270,000 shares of Xenon Pharmaceuticals stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $60.33, for a total transaction of $16,289,100.00. Following the completion of the transaction, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at $361,980. This trade represents a 97.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Andrea Difabio sold 2,607 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total value of $156,706.77. Following the completion of the transaction, the insider directly owned 4,893 shares in the company, valued at $294,118.23. The trade was a 34.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 336,707 shares of company stock valued at $19,622,565 in the last ninety days. Insiders own 4.07% of the company’s stock.

Analyst Upgrades and Downgrades

XENE has been the subject of a number of recent research reports. Chardan Capital upgraded shares of Xenon Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, November 19th. Stifel Nicolaus set a $66.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 10th. Jefferies Financial Group set a $100.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Wedbush increased their price target on shares of Xenon Pharmaceuticals from $47.00 to $64.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 10th. Finally, Robert W. Baird raised their price target on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an “outperform” rating in a research note on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $71.94.

Key Headlines Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase‑3 progress — Xenon completed the X‑TOLE2 Phase 3 study, placing XEN1101 (azetukalner) in focus for epilepsy investors and supporting a planned NDA timeline; this derisks the lead program and underpins longer‑term commercial value. Read More.
• Positive Sentiment: Big institutional interest — Reports note major funds increasing exposure (including a ~$200M position cited by The Motley Fool), which can add buying pressure into the stock on further positive catalysts. Read More.
• Positive Sentiment: Balance‑sheet boost — Xenon closed an upsized public offering that raised approximately $747.5M of gross proceeds, extending runway for Phase 3/commercial preparations and reducing near‑term financing risk. Read More.
• Positive Sentiment: Analyst upgrades — Several brokers raised price targets and reiterated Buy/Overweight ratings (Deutsche Bank, HC Wainwright, Wells Fargo and others), which can support short‑term demand. Read More.
• Neutral Sentiment: Model adjustments — HC Wainwright revised multi‑year EPS forecasts (improving FY2028–FY2030 assumptions but nudging FY2027), reflecting evolving commercialization timing; useful for context but subject to change. Read More.
• Neutral Sentiment: Volume and momentum — The stock has seen elevated trading volume following the analyst activity and trial news, which can amplify intraday moves in either direction. Read More.
• Negative Sentiment: Insider selling — CEO Ian Mortimer and several other insiders disclosed large open‑market sales (hundreds of thousands of shares by the CEO), reducing insider ownership and raising optics concerns for some investors. Read More.
• Negative Sentiment: Dilution risk — The sizable share issuance (and initial underwriter option) that funded the ~$747.5M raise increases outstanding shares and can pressure near‑term per‑share metrics despite improving cash runway. Read More.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.